A 25-year-old woman with type 2 diabetes and liver disease
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
A 25-year-old woman with type 2 diabetes and liver disease. / Junker, Anders Ellekær; Gluud, Lise Lotte; Pedersen, Jens; Langhoff, Jill Levin; Holst, Jens Juul; Knop, Filip Krag; Vilsbøll, Tina.
In: Case Reports in Gastroenterology, Vol. 8, No. 3, 2014, p. 398-403.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - A 25-year-old woman with type 2 diabetes and liver disease
AU - Junker, Anders Ellekær
AU - Gluud, Lise Lotte
AU - Pedersen, Jens
AU - Langhoff, Jill Levin
AU - Holst, Jens Juul
AU - Knop, Filip Krag
AU - Vilsbøll, Tina
PY - 2014
Y1 - 2014
N2 - A 25-year-old female nurse was referred to our diabetes outpatient clinic with poorly controlled type 2 diabetes, obesity and elevated liver function tests (LFTs). Following a liver biopsy she was diagnosed with non-alcoholic steatohepatitis (NASH) and liver fibrosis. Treatment with subcutaneous injections of the glucagon-like peptide-1 receptor (GLP-1R) agonist liraglutide was initiated. After 46 weeks of treatment the patient had lost 16 kg, glycemic control was excellent and LFTs had normalized. Repeat liver biopsy and ultrasound showed reduction in hepatic fat content and inflammatory cells. The biopsy no longer fulfilled the criteria for NASH. The liver biopsies did not express hepatic GLP-1Rs using quantitative polymerase chain reaction. Our case suggests that liraglutide may benefit patients with NASH.
AB - A 25-year-old female nurse was referred to our diabetes outpatient clinic with poorly controlled type 2 diabetes, obesity and elevated liver function tests (LFTs). Following a liver biopsy she was diagnosed with non-alcoholic steatohepatitis (NASH) and liver fibrosis. Treatment with subcutaneous injections of the glucagon-like peptide-1 receptor (GLP-1R) agonist liraglutide was initiated. After 46 weeks of treatment the patient had lost 16 kg, glycemic control was excellent and LFTs had normalized. Repeat liver biopsy and ultrasound showed reduction in hepatic fat content and inflammatory cells. The biopsy no longer fulfilled the criteria for NASH. The liver biopsies did not express hepatic GLP-1Rs using quantitative polymerase chain reaction. Our case suggests that liraglutide may benefit patients with NASH.
U2 - 10.1159/000369968
DO - 10.1159/000369968
M3 - Journal article
C2 - 25606030
VL - 8
SP - 398
EP - 403
JO - Case Reports in Gastroenterology
JF - Case Reports in Gastroenterology
SN - 1662-0631
IS - 3
ER -
ID: 132046734